The European Drug Checking Trends 2018–2024 report offers a unique multi-year analysis of changes in drug markets across Europe. From shifts in MDMA purity to recent trends in cocaine adulteration and the growing risks of nitazene opioids to people using benzodiazepines, this report highlights key developments impacting harm reduction.
Drug checking plays a crucial role in monitoring these trends, but services remain unevenly distributed across Europe. Enhanced funding and resources are vital to strengthen their impact on public health.
